Literature DB >> 19732481

Antidepressant study design affects patient expectancy: a pilot study.

B Rutherford1, J Sneed, D Devanand, R Eisenstadt, S Roose.   

Abstract

BACKGROUND: Response to antidepressant medication is higher in comparator versus placebo-controlled randomized controlled trials (RCTs). Patient expectancy is an important influence on clinical outcome in the treatment of depression and may explain this finding. The results are reported from a pilot RCT studying expectancy and depression outcome in placebo-controlled versus comparator treatment conditions.MethodOut-patients aged 18-65 years with major depressive disorder (MDD) were enrolled in this 8-week RCT. Subjects were randomized to placebo-controlled (escitalopram or placebo) or comparator (escitalopram or citalopram) administration of antidepressant medication. Subjects reported their expected likelihood and magnitude of depression improvement before and after randomization using questions from the Credibility and Expectancy Scale (CES). A regressed change model of post-randomization expectancy of improvement was fit to the data to determine whether subjects in the comparator group reported greater expectancies of improvement than subjects in the placebo-controlled group.
RESULTS: Twenty subjects with mean age 56.5+/-11.7 years, a baseline Hamilton Depression Rating Scale (HAMD) score of 24.2+/-5.3, baseline Beck Depression Inventory (BDI) score of 24.9+/-6.4 and baseline Clinical Global Impressions (CGI) - Severity score of 4.0+/-0.3 were enrolled in the study. Adjusting for other factors, the effect of group assignment on expected magnitude of improvement was significant and large (effect size 1.5). No group differences in expected likelihood of improvement were found.
CONCLUSIONS: Randomization to comparator versus placebo-controlled administration of antidepressant medication produced greater expectancies of how much patients would improve during the trial. This expectancy difference may explain the higher response and remission rates that are observed in comparator versus placebo-controlled trials.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19732481      PMCID: PMC3784014          DOI: 10.1017/S0033291709991085

Source DB:  PubMed          Journal:  Psychol Med        ISSN: 0033-2917            Impact factor:   7.723


  22 in total

1.  Psychometric properties of the credibility/expectancy questionnaire.

Authors:  G J Devilly; T D Borkovec
Journal:  J Behav Ther Exp Psychiatry       Date:  2000-06

2.  Expectation modulates the response to subthalamic nucleus stimulation in Parkinsonian patients.

Authors:  Antonella Pollo; Elena Torre; Leonardo Lopiano; Mario Rizzone; Michele Lanotte; Andrea Cavanna; Bruno Bergamasco; Fabrizio Benedetti
Journal:  Neuroreport       Date:  2002-08-07       Impact factor: 1.837

3.  Does study design influence outcome?. The effects of placebo control and treatment duration in antidepressant trials.

Authors:  Bret R Rutherford; Joel R Sneed; Steven P Roose
Journal:  Psychother Psychosom       Date:  2009-03-24       Impact factor: 17.659

Review 4.  Expectancy factors in the treatment of fear: methodological and theoretical issues.

Authors:  J Lick; R Bootzin
Journal:  Psychol Bull       Date:  1975-11       Impact factor: 17.737

Review 5.  Depression and heart disease: evidence of a link, and its therapeutic implications.

Authors:  Wei Jiang; Ranga R K Krishnan; Christopher M O'Connor
Journal:  CNS Drugs       Date:  2002       Impact factor: 5.749

Review 6.  Expectancy of therapeutic gain: an empirical and conceptual critique.

Authors:  W Wilkins
Journal:  J Consult Clin Psychol       Date:  1973-02

Review 7.  Placebo response in studies of major depression: variable, substantial, and growing.

Authors:  B Timothy Walsh; Stuart N Seidman; Robyn Sysko; Madelyn Gould
Journal:  JAMA       Date:  2002-04-10       Impact factor: 56.272

8.  Residual symptoms at remission from depression: impact on long-term outcome.

Authors:  N Kennedy; E S Paykel
Journal:  J Affect Disord       Date:  2004-06       Impact factor: 4.839

9.  The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R).

Authors:  Ronald C Kessler; Patricia Berglund; Olga Demler; Robert Jin; Doreen Koretz; Kathleen R Merikangas; A John Rush; Ellen E Walters; Philip S Wang
Journal:  JAMA       Date:  2003-06-18       Impact factor: 56.272

10.  Subject expectations of treatment effectiveness and outcome of treatment with an experimental antidepressant.

Authors:  Heather V Krell; Andrew F Leuchter; Melinda Morgan; Ian A Cook; Michelle Abrams
Journal:  J Clin Psychiatry       Date:  2004-09       Impact factor: 4.384

View more
  9 in total

1.  Therapeutic alliance in antidepressant treatment: cause or effect of symptomatic levels?

Authors:  Sigal Zilcha-Mano; Steven P Roose; Jacques P Barber; Bret R Rutherford
Journal:  Psychother Psychosom       Date:  2015-03-28       Impact factor: 17.659

2.  Improving study design for antidepressant effectiveness assessment.

Authors:  Florian Naudet; Bruno Millet; Jean Michel Reymann; Bruno Falissard
Journal:  Int J Methods Psychiatr Res       Date:  2013-08-30       Impact factor: 4.035

3.  Predicting individual differences in placebo analgesia: contributions of brain activity during anticipation and pain experience.

Authors:  Tor D Wager; Lauren Y Atlas; Lauren A Leotti; James K Rilling
Journal:  J Neurosci       Date:  2011-01-12       Impact factor: 6.167

Review 4.  Deconstructing pediatric depression trials: an analysis of the effects of expectancy and therapeutic contact.

Authors:  Bret R Rutherford; Joel R Sneed; Jane M Tandler; David Rindskopf; Bradley S Peterson; Steven P Roose
Journal:  J Am Acad Child Adolesc Psychiatry       Date:  2011-06-15       Impact factor: 8.829

5.  Does differential drop-out explain the influence of study design on antidepressant response? A meta-analysis.

Authors:  Bret R Rutherford; Joel R Sneed; Steven P Roose
Journal:  J Affect Disord       Date:  2012-03-02       Impact factor: 4.839

6.  A randomized, prospective pilot study of patient expectancy and antidepressant outcome.

Authors:  B R Rutherford; S M Marcus; P Wang; J R Sneed; G Pelton; D Devanand; N Duan; S P Roose
Journal:  Psychol Med       Date:  2012-09-13       Impact factor: 7.723

Review 7.  Usual and unusual care: existing practice control groups in randomized controlled trials of behavioral interventions.

Authors:  Kenneth E Freedland; David C Mohr; Karina W Davidson; Joseph E Schwartz
Journal:  Psychosom Med       Date:  2011-05-02       Impact factor: 4.312

Review 8.  Common Factors in Pediatric Psychiatry: A Review of Essential and Adjunctive Mechanisms of Treatment Outcome.

Authors:  Alessandro S De Nadai; Marc S Karver; Tanya K Murphy; Mark A Cavitt; Jeffrey L Alvaro; Michael Bengtson; Saundra Stock; Andrew C Rakhshani; Eric A Storch
Journal:  J Child Adolesc Psychopharmacol       Date:  2016-04-29       Impact factor: 2.576

9.  A randomised cross-over study assessing the "blue pyjama syndrome" in major depressive episode.

Authors:  Hélèna Delmas; Jean-Marie Batail; Bruno Falissard; Gabriel Robert; Maxence Rangé; Stéphane Brousse; Jacques Soulabaille; Dominique Drapier; Florian Naudet
Journal:  Sci Rep       Date:  2017-06-01       Impact factor: 4.379

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.